{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:15:37Z","timestamp":1789708537663,"version":"4.0.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Clinical Electrophysiology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jacep.2022.08.004","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T16:50:09Z","timestamp":1666803009000},"page":"1393-1404","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"title":["Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors on Outcomes\u00a0After Catheter Ablation for\u00a0Atrial Fibrillation"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8948-0869","authenticated-orcid":false,"given":"Hideyuki","family":"Kishima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanao","family":"Mine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Kitagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Asakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacep.2022.08.004_bib1","first-page":"840","article-title":"Independent risk factors for atrial fibrillation in a population-based cohort","volume":"271","author":"Benjamin","year":"1994","journal-title":"The Framingham Heart Study. JAMA"},{"key":"10.1016\/j.jacep.2022.08.004_bib2","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s11606-010-1340-y","article-title":"Diabetes mellitus, glycemic control, and risk of atrial fibrillation","volume":"25","author":"Dublin","year":"2010","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.jacep.2022.08.004_bib3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4239\/wjd.v7.i3.45","article-title":"Role of diabetes in heart rhythm disorders","volume":"7","author":"Koektuerk","year":"2016","journal-title":"World J Diabetes"},{"key":"10.1016\/j.jacep.2022.08.004_bib4","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacep.2022.08.004_bib5","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacep.2022.08.004_bib6","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacep.2022.08.004_bib7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","article-title":"Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors","volume":"14","author":"Grempler","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacep.2022.08.004_bib8","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","article-title":"Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 Trial","volume":"141","author":"Zelniker","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacep.2022.08.004_bib9","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/dom.13077","article-title":"Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: a multinational observational study","volume":"20","author":"Persson","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacep.2022.08.004_bib10","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S2213-8587(17)30258-9","article-title":"Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis","volume":"5","author":"Birkeland","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacep.2022.08.004_bib11","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.jacc.2022.03.337","article-title":"The Increasing Role of Rhythm Control in Patients With Atrial Fibrillation: JACC State-of-the-Art Review","volume":"79","author":"Camm","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacep.2022.08.004_bib12","doi-asserted-by":"crossref","first-page":"332","DOI":"10.5105\/jse.23.332","article-title":"A\u00a0new method for evaluating quality of life specific to patients with atrial fibrillation: atrial fibrillation Quality of Life Questionnaire (AFQLQ). Article in Japanese","volume":"23","author":"Yamashita","year":"2003","journal-title":"Jpn J Electrocardiol"},{"key":"10.1016\/j.jacep.2022.08.004_bib13","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jacep.2022.08.004_bib14","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1111\/j.1538-7836.2011.04378.x","article-title":"Bleeding risk in 'real world' patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort","volume":"9","author":"Olesen","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jacep.2022.08.004_bib15","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/dom.13512","article-title":"Atrial fibrillation and type 2 diabetes: prevalence, etiology, pathophysiology and effect of anti-diabetic therapies","volume":"21","author":"Bell","year":"2019","journal-title":"Diabetes Obes Merab"},{"key":"10.1016\/j.jacep.2022.08.004_bib16","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.amjcard.2011.03.004","article-title":"Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation","volume":"108","author":"Huxley","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacep.2022.08.004_bib17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.pcad.2019.03.003","article-title":"Diabetic cardiomyopathy\u2014a comprehensive updated review","volume":"62","author":"Murtaza","year":"2019","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.jacep.2022.08.004_bib18","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/j.1540-8167.2006.00528.x","article-title":"What are arrhythmogenic substrates in diabetic rat atria?","volume":"17","author":"Kato","year":"2006","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jacep.2022.08.004_bib19","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ijcard.2015.03.052","article-title":"Diabetes mellitus and atrial fibrillation: pathophysiological mechanisms and potential upstream therapies","volume":"184","author":"Goudis","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacep.2022.08.004_bib20","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.jacc.2019.07.020","article-title":"Atrial fibrillation and diabetes mellitus: JACC Review Topic of the Week","volume":"74","author":"Wang","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacep.2022.08.004_bib21","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/j.jacc.2017.09.002","article-title":"Obesity and atrial fibrillation prevalence, pathogenesis, and prognosis: effects of weight loss and exercise","volume":"70","author":"Alvie","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacep.2022.08.004_bib22","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12933-019-0964-4","article-title":"Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet\/streptozotocin-induced diabetic rats","volume":"18","author":"Shao","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacep.2022.08.004_bib23","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12933-020-01162-w","article-title":"The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors","volume":"19","author":"Ling","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacep.2022.08.004_bib24","doi-asserted-by":"crossref","first-page":"H86","DOI":"10.1152\/ajpheart.00010.2012","article-title":"Conduction and refractory disorders in the diabetic atrium","volume":"303","author":"Watanabe","year":"2012","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jacep.2022.08.004_bib25","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/j.jacc.2009.07.031","article-title":"Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart","volume":"54","author":"Anderson","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacep.2022.08.004_bib26","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/nature12537","article-title":"Diabetic hyperglycemia activates CaMKII and arrhythmias by O-linked glycosylation","volume":"502","author":"Erickson","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.jacep.2022.08.004_bib27","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12933-019-0984-0","article-title":"Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?","volume":"19","author":"Yurista","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacep.2022.08.004_bib28","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12933-017-0658-8","article-title":"The effect of\u00a0dapagliflozin treatment on epicardial adipose\u00a0tissue volume","volume":"17","author":"Sato","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacep.2022.08.004_bib29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/cvr\/cvu045","article-title":"Epicardial adipose tissue and atrial fibrillation","volume":"102","author":"Hatem","year":"2014","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacep.2022.08.004_bib30","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s13300-017-0232-0","article-title":"Effects of canagliflozin on serum magnesium in patients with type 2 diabetes mellitus: a post hoc analysis of randomized controlled trials","volume":"8","author":"Gilbert","year":"2017","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jacep.2022.08.004_bib31","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/dom.13101","article-title":"Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials","volume":"20","author":"Zhao","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacep.2022.08.004_bib32","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.amjcard.2014.10.041","article-title":"Anemia and reduced kidney function as risk factors for new onset of atrial fibrillation (from the Ibaraki Prefectural Health Study)","volume":"115","author":"Xu","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacep.2022.08.004_bib33","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ahj.2009.06.031","article-title":"Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata Preventive Medicine Study","volume":"158","author":"Watanabe","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacep.2022.08.004_bib34","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/01.mnh.0000165895.90748.3b","article-title":"What is the evidence that microalbuminuria is a predictor of cardiovascular disease events?","volume":"14","author":"Yuyun","year":"2005","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.jacep.2022.08.004_bib35","article-title":"Association of proteinuria and incident atrial fibrillation in patients with diabetes mellitus: a population-based senior cohort study","volume":"11","author":"Kim","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacep.2022.08.004_bib36","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.2215\/CJN.01860217","article-title":"eGFR and albuminuria in relation to risk of incident atrial fibrillation: a meta-analysis of the Jackson Heart Study, the Multi-Ethnic Study of Atherosclerosis, and the Cardiovascular Health Study","volume":"12","author":"Bansal","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacep.2022.08.004_bib37","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacep.2022.08.004_bib38","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.jacc.2020.12.065","article-title":"Therapeutic potential of ketone bodies for patients with cardiovascular disease: JACC State-of-the-Art Review","volume":"77","author":"Yurista","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacep.2022.08.004_bib39","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1681\/ASN.2008030292","article-title":"First morning voids are more reliable than spot urine samples to assess microalbuminuria","volume":"20","author":"Witte","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"}],"container-title":["JACC: Clinical Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405500X22006697?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405500X22006697?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T07:31:18Z","timestamp":1762500678000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405500X22006697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S2405500X22006697"],"URL":"https:\/\/doi.org\/10.1016\/j.jacep.2022.08.004","relation":{},"ISSN":["2405-500X"],"issn-type":[{"value":"2405-500X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors on Outcomes\u00a0After Catheter Ablation for\u00a0Atrial Fibrillation","name":"articletitle","label":"Article Title"},{"value":"JACC: Clinical Electrophysiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacep.2022.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}